Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

63.08 +0.93 (+1.50%)
Delayed Quote Updated: 12:52 PM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell ↗
Royalty Pharma lets dividend lovers invest in the pharmaceutical sector in a unique and sustainable way. 
Via The Motley Fool
Topics Economy
News headline image
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? ↗
Investors are catching on to this rare gem among pharmaceutical stocks, but thanks to promising growth and a low valuation, further upside remains. 
Via The Motley Fool
News headline image
Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts ↗
Royalty Pharma (NASDAQ:RPRX) executives said the company is monitoring a shifting biopharma policy environment, expanding its artificial-intelligence capabilities and building a presence in China,... 
Via MarketBeat
Topics Artificial Intelligence
Royalty Pharma (NASDAQ:RPRX) Hits Perfect Technical Rating with Breakout Setup ↗
Via Chartmill
Royalty Pharma (NASDAQ:RPRX) Beats Q2 Revenue Estimates, Raises Full-Year Guidance ↗
Via Chartmill
Royalty Pharma (NASDAQ:RPRX) Beats Q1 Estimates and Raises Guidance, Fueling Strong Momentum ↗
Via Chartmill
Royalty Pharma PLC (NASDAQ:RPRX) Emerges as a Compelling Value Investment ↗
Via Chartmill
News headline image
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? ↗
Revolution Medicines' stock is up 330% in a year on drug development progress; you may want to spread your bets with Royalty Pharma instead. 
Via The Motley Fool
News headline image
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today ↗
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 15 years by 4.89% on an annualized basis producing an average annual return of 18.08%. Currently, Royalty Pharma has a market... 
Via Benzinga
News headline image
If You Invested $1000 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today ↗
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 27.34% on an annualized basis producing an average annual return of 40.75%. Currently, Royalty Pharma has a market... 
Via Benzinga
News headline image
Here’s How Much You Would Have Made Owning Royalty Pharma Stock In The Last 10 Years ↗
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annualized basis producing an average annual return of 39.56%. Currently, Royalty Pharma has a market... 
Via Benzinga
ROYALTY PHARMA PLC-CL A (NASDAQ:RPRX) Shows High Technical and Setup Ratings Ahead of Potential Breakout ↗
Via Chartmill
News headline image
Royalty Pharma (RPRX) Q2 2026 Earnings Call Transcript ↗
Royalty receipts surged 14% as guidance raised for second consecutive quarter. 
Via The Motley Fool
Topics Earnings
News headline image
Royalty Pharma Q2 Earnings Call Highlights ↗
Royalty Pharma (NASDAQ:RPRX) raised its 2026 outlook for the second consecutive quarter after reporting higher second-quarter royalty receipts, continued capital deployment and progress across its... 
Via MarketBeat
Topics Earnings
News headline image
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (N... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Unpopular Stocks We’re Skeptical Of
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord... 
Via StockStory
News headline image
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings?
Royalty Pharma has been on fire lately. In the past six months alone, the company’s stock price has rocketed 46.3%, reaching $55.73 per share. This performan... 
Via StockStory
Topics Supply Chain
News headline image
Mattel Stock Is Down 24%. Here's What a $50.9 Million Exit Could Mean ↗
Mattel is a global toy and entertainment company behind brands like Barbie, Hot Wheels, and Fisher-Price, serving families worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst Questions
Royalty Pharma’s first quarter results surpassed Wall Street’s revenue and adjusted EBITDA expectations, driven by robust growth across its diversified royal... 
Via StockStory
Topics Earnings
News headline image
Why One Fund’s $4 Million Centerra Gold Exit Looks Like Profit-Taking Amid a 150% Rally ↗
Centerra Gold operates integrated mining projects in North America and Turkey, generating revenue from gold, copper, and molybdenum sales. 
Via The Motley Fool
News headline image
This Fund Cashed Out of Preformed Line Products Amid a 150% Stock Surge ↗
Preformed Line Products designs and manufactures network hardware for utilities and telecoms across global infrastructure markets. 
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
Royalty Pharma (RPRX) Q1 2026 Earnings Transcript ↗
Royalty Pharma (RPRX) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings this Wednesday before market hours. Here’s what investors should know. R... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Unpopular Stocks We’re Skeptical Of
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
News headline image
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali... 
Via StockStory
News headline image
Branded Pharmaceuticals Stocks Q4 Teardown: Royalty Pharma (NASDAQ:RPRX) Vs The Rest
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Value Stock for Long-Term Investors and 2 Facing Challenges
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t... 
Via StockStory
News headline image
1 Cash-Producing Stock to Own for Decades and 2 That Underwhelm
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
Topics Energy
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)... 
Via Finterra
Topics Economy Initial Public Offering
News headline image
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings?
Royalty Pharma has had an impressive run over the past six months. While the S&P 500 has been flat, the stock has returned 31.5% and now trades at $45.91. Th... 
Via StockStory
Topics Artificial Intelligence Stocks Supply Chain
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.